Chris Boshoff: Topline Overall Survival Results in Non-Metastatic Castration-Sensitive Prostate Cancer
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“At ASCO along with our partner Astellas Pharma, we announced long-term follow-up data in metastatic castration-sensitive Prostate Cancer (CSPC).
And now, we’re pleased to share an update even earlier in the disease continuum: topline overall survival results are now available in men with non-metastatic CSPC with biochemical recurrence (BCR) at high risk for metastasis.
Among men who have undergone definitive prostate cancer treatment, an estimated 20-40% will experience BCR within 10 years, and about nine out of 10 men with high-risk BCR will go on to develop metastatic disease, underscoring the significant need for earlier intervention.
Today’s results are a meaningful advance for patients and add to the robust clinical support for our androgen receptor inhibitor across the spectrum of advanced prostate cancer.”
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023